| Document |
Document Title |
|
WO/2017/092638A1 |
The present invention relates to an opioid receptor antagonist derivative, a preparation method thereof and a use thereof in medicine. In particular, the present invention relates to a naloxone derivative as shown by general formula (I) ...
|
|
WO/2017/084431A1 |
The present invention provides a composition for removing harmful reactive oxygen from a human body, which is composed of 7-hydroxycoumarin for removing superoxide radical O2 and resveratrol for removing hydrogen peroxide H2O2, the 7-hyd...
|
|
WO/2017/087795A1 |
This invention relates to novel α-tocotrienol quinones of Formula I: (I), and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions ...
|
|
WO/2017/083776A9 |
The invention provides for AAV vectors expressing the ANO5 gene and antioxidant therapy as methods of inducing muscle regeneration and a method of treating muscular dystrophy.
|
|
WO/2017/080669A1 |
The present invention provides a pharmaceutical preparation for use by injection into the skin, wherein the pharmaceutical preparation is preparable by a production method comprising the steps of providing a liquid collected from an orga...
|
|
WO/2017/080668A1 |
The present invention relates a pharmaceutical preparation for the treatment of age- related disorders, which is preparable by a production method comprising the following steps: providing a liquid collected from an organism, which liqui...
|
|
WO/2017/083776A1 |
The invention provides for AAV vectors expressing the ANO5 gene and antioxidant therapy as methods of inducing muscle regeneration and a method of treating muscular dystrophy.
|
|
WO/2017/075696A1 |
Mycotoxin-deactivating aptamers, especially DNA aptamers, bind to mycotoxins in feed and feed ingredients resulting in the reduction or elimination of toxic and carcinogenic effects of mycotoxins. The invention also discloses a compositi...
|
|
WO/2017/079455A1 |
Disclosed herein is the novel use of use of a Bauhinia spp. extract, which may upregulate neprilysin, induce autophagy, protect neuron from amyloidopathy or tauopathy, and/or promote neurite outgrowth, thus the Bauhinia spp. extract of t...
|
|
WO/2017/077516A2 |
The invention relates to compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions, particularly wherein said telomere related diseases and/or telomere related medical conditions are cance...
|
|
WO/2017/075899A1 |
The present invention provides an application of a PprI protein in preparation of a drug for prevention and treatment of radiation damage of higher eukaryotes. The PprI protein can prevent and treat acute radiation damage of human cells ...
|
|
WO/2017/077516A3 |
The invention relates to compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions, particularly wherein said telomere related diseases and/or telomere related medical conditions are cance...
|
|
WO/2017/063328A1 |
A fullerene and/or metallofullerene micronano material and application thereof. The fullerene and/or metallofullerene micronano material has all the following properties: (1) the surface is hydrophilic, so that the micronano material is ...
|
|
WO/2017/063064A1 |
The present invention relates to a method for producing an equine serum against the venom of Apis mellifera africanised bees, produced from the blood of hyperimmunised horses, and using as the antigen the main toxic fractions of the veno...
|
|
WO/2017/060914A2 |
Penicillamine and its derivatives, composition, methods of synthesizing and using the compound of formula 1 are disclosed. The compounds of formula 1 also comprises of salts, polymorphs, solvates and hydrates thereof. The compounds may b...
|
|
WO/2017/060914A3 |
Penicillamine and its derivatives, composition, methods of synthesizing and using the compound of formula 1 are disclosed. The compounds of formula 1 also comprises of salts, polymorphs, solvates and hydrates thereof. The compounds may b...
|
|
WO/2017/062311A1 |
Compositions for addressing one or more of the effects of aging are described. The compositions comprise a first component comprising repair system activator(s) such as nicotinamide adenine dinucleotide (NAD+), nicotinamide mononucleotid...
|
|
WO/2017/057647A1 |
Provided is a method for producing an olive leaf extract that contains a high concentration of oleuropein. The method according to the present invention for producing an olive leaf extract comprises a first step for grinding dried olive ...
|
|
WO/2017/057768A1 |
The present invention addresses the problem of providing an intraocular perfusion solution that is able to adequately protect intraocular tissue during eye surgery, and which is highly safe. The problem is solved by an intraocular perfus...
|
|
WO/2017/058063A1 |
The invention relates to an agent which has both a protective effect on healthy organs and tissues and an adjuvant effect during radiotherapy and chemotherapy.
|
|
WO/2017/051585A1 |
[Problem] To provide an inhaling fragrance that can be taken in other than through oral administration. [Solution] The inhaling fragrance includes leaf alcohol and linalool, includes ethanol as a primary solvent, and is liquid at normal ...
|
|
WO/2017/050298A1 |
The present invention relates to compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof.
|
|
WO/2017/045034A1 |
The present invention provides an advantageous formulation of ubiquinone (CoQ10) and/or ubiquinol with greater bioavailability, thereby allowing for high concentrations of CoQ10 and/or ubiquinol to be absorbed with lesser volumes of the ...
|
|
WO/2017/042267A1 |
The present invention relates to the use of compounds for the prevention and treatment of diseases whose initiation and/or evolution relates to the production and effects of reactive oxygen species (ROS) of mitochondrial origin.
|
|
WO/2017/024639A1 |
A Chinese medicine hangover curing agent. The agent is prepared from Chinese Hawthorn, Folium nelumbinis, Folium mori, Taraxaci herba, Lophatheri herba, common duckweed and tangerine leaves.
|
|
WO/2017/022030A1 |
Provided is a method for producing an extract of Momordica charantia var. pavel, said extract containing less than 5 ppm of quinine. The method for producing an extract of M. charantia var. pavel comprises a cultivation step, a harvestin...
|
|
WO/2017/021914A1 |
This document provides methods and materials for reducing the degree of damage to tissue transplanted into a mammal following transplantation. For example, methods and materials for using abscisic acid to reduce tissue damage to vascular...
|
|
WO/2017/014340A1 |
The present invention relates to a composition containing Stephanandra incisa (Thunb.) Zabel extracts having an anti-aging efficacy and a use containing the same as an active ingredient. The present invention provides Stephanandra incisa...
|
|
WO/2017/013492A1 |
The present disclosure provides compositions comprising 15-HEPE for use in treating and/or preventing cancer and neurological diseases in a subject in need thereof.
|
|
WO2017010538A1 |
Provided are a carnosine dipeptidase 1 inhibitor composition, a use for a material that inhibits carnosine dipeptidase 1, and a method for inhibiting carnosine dipeptidase 1. The present invention demonstrates the discovery of a plant- o...
|
|
WO/2017/009202A1 |
This invention relates generally to compositions and methods for combating inflammatory disease and particularly to the use of food and/or feed compositions for preventing, reducing and/or treating inflammatory disorders, diseases, or di...
|
|
WO/2017/010537A1 |
Provided are a carnosine dipeptidase 1 inhibitor composition, a use for said composition in order to inhibit carnosine dipeptidase 1, and a method for inhibiting carnosine dipeptidase 1. The present invention demonstrates the discovery o...
|
|
WO/2017/008902A1 |
Pharmaceutically acceptable cholecalciferol sulfate salts are used for combating vitamin D3deficiency. The invention also relates to cholecalciferol sulfate salts and to pharmaceutical compositions of the pharmaceutically acceptable chol...
|
|
WO/2017/010133A1 |
Provided are a carnosine dipeptidase 1 inhibitor composition, a use for a material that inhibits carnosine dipeptidase 1, and a method for inhibiting carnosine dipeptidase 1. The present invention demonstrates the discovery of a plant- o...
|
|
WO/2016/206363A1 |
A use of a Jilin ginseng oligopeptide in preparation of an anti-oxidant food product or a health care food product.
|
|
WO/2016/210226A1 |
The present invention provides a formulation of Coenzyme Q10 that can be re-dispersed from a stable dry powder to formulation to yield a nanodispersion that can be readily aerosolized for inhalation.
|
|
WO/2016/198401A1 |
A series of substituted indazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neuro...
|
|
WO/2016/188766A1 |
The present invention relates to compounds for prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially to compounds for prophylaxis or treatment of di...
|
|
WO/2016/190750A1 |
Improving the antioxidant capacity in an animal by increasing the level of glutathione in the blood or tissue of the animal comprising providing a composition containing beta- casein to the animal for consumption, where the beta-casein c...
|
|
WO/2016/187545A1 |
This invention relates to compositions and methods for treating, ameliorating and preventing the toxic effects of venom poisoning. In particular, the invention provides compositions comprising carbon monoxide releasing molecules (CORM) o...
|
|
WO/2016/185403A1 |
The present application refers to the development of a new effective antidote for the poisonous Amanita mushroom species, after exploring an innovative in silico and in vivo approach based on the binding site of amatoxin to RNA polymeras...
|
|
WO/2016/177309A1 |
Provided is a method for preparing a broccoli protein peptide. The method uses a broccoli protein as the raw material, and obtains a broccoli protein peptide powder through the steps of preprocessing, enzymatic hydrolysis, terminating en...
|
|
WO/2016/174367A1 |
The present invention relates to a bioassimilable protein-melanin complex, advantageously soluble in water, comprising a protein extract, advantageously rich in S-sulfonated residues and melanin. The claimed complex further exhibits subs...
|
|
WO/2016/171640A8 |
The invention relates to pharmacology and may be used for producing medicinal agents for treating and preventing viral diseases caused by the herpes, influenza and hepatitis B and C viruses, and also virus-induced immunodeficiencies. A b...
|
|
WO/2016/171640A1 |
The invention relates to pharmacology and may be used for producing medicinal agents for treating and preventing viral diseases caused by the herpes, influenza and hepatitis B and C viruses, and also virus-induced immunodeficiencies. A b...
|
|
WO/2016/169353A1 |
A compound beverage for clearing heat and a preparation method therefor. The compound beverage is prepared from the following components in parts by weight: 15 to 20 parts of white fungus, 3 to 7 parts of bulbus lilii, 1 to 5 parts of se...
|
|
WO/2016/168670A3 |
The present disclosure relates to methods of extending the lifespan of a subject or treating, suppressing, inhibiting or delaying the onset of an age-related condition or disorder, such as cancer, in a subject. The methods comprise admin...
|
|
WO/2016/161501A1 |
The present application provides pharmaceutical compositions comprising polyanionic and polynon-ionic cyclodextrin-based dendrimers. The compositions can be used as excipients, or to bind to compounds such as in the use as a rescue medic...
|
|
WO/2016/162870A1 |
Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Va...
|
|
WO/2016/149886A1 |
Uses of a multipolar microkinetic drinking water in preparing a drink, healthcare product or medicament for use in reducing blood urea. The multipolar microkinetic drinking water is prepared from raw drinking water being passed through a...
|
